Objective The objective of this study was to evaluate the impact of pregnancy history and 17-hydroxyprogesterone caproate (17-OHPC) treatment on cervical fluid cytokines and matrix metalloproteinases (MMPs). Study Design Cervical fluid was obtained between 16 0/7 and 24 6/7 weeks from women with only prior term births (controls, n ¼ 26), women with one or more prior spontaneous preterm births (SPTBs) choosing to receive 17-OHPC (17-OHPC, n ¼ 24), or to not receive 17-OHPC (refusers, n ¼ 12). Cervical fluid collections were repeated 2, 4, and 8 weeks after the first sample and concentrations of MMPs and cytokines were measured by multiplex immune assay.
Supplemental progesterone treatment is commonly utilized to reduce spontaneous preterm birth (SPTB) risk.
1,2 One such progestin, intramuscular 17-hydroxyprogesterone caproate (17-OHPC) reduces the risk of SPTB in women with prior preterm birth (PTB) by one-third. 1 Despite widespread use of 17-OHPC for reducing PTB risk, the target of this treatment remains elusive. Identification of specific treatment-responsive pharmacodynamic marker or markers could provide insight into the biological pathways leading to PTB and could allow for development of more effective treatments. The lack of a recognized target for 17-OHPC is not the only pharmacologic deficiency of this medication; the appropriate dose is also unclear. Current treatment utilizes a fixed dose of 250 mg weekly which is not based on any pharmacologic considerations. Ideally, dose-response studies are needed to define an optimal dose, but these have not been performed for 17-OHPC. This omission hampers the assessment of efficacy for this medication which has been judged by the rates of SPTB in a treated versus a control group. The absence of dose-response studies to establish the optimal dose is clearly an issue for 17-OHPC. Plasma concentrations at steady state with the weekly 250 mg dose vary from 3 to 56 ng/mL and plasma concentrations impact efficacy. 3 If an intermediate pharmacodynamic end point for SPTB could be identified for this treatment, such a marker could be utilized to optimize a dosing regimen without the need for a large multicenter dose ranging study. Furthermore, by identifying a biomarker of SPTB risk in addition to history alone, further risk stratification would be possible. Identifying women at the highest risk utilizing both an individual's PTB history and a biomarker of risk would enable focused 17-OHPC treatments in an enriched high-risk group. This study focuses on the cervix for potential biomarkers of SPTB. A large body of literature has established that cervical length in the second trimester is an excellent predictor of SPTB risk. 4, 5 Cervical biomarkers during pregnancy that might serve as pharmacodynamic end points for 17-OHPC therapy are mostly limited to ultrasound imaging of cervical structure, digital examination, and examination of the cervicovaginal fluid. Several inflammatory cytokines and matrix metalloproteinases (MMPs) have been associated with SPTB. [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] The objective of this pilot study was to evaluate cervical cytokines and MMPs as potential targets of intramuscular 17-OHPC therapy and to determine if those potential targets are impacted by pregnancy history.
Materials and Methods

Study Design
This was a multicenter prospective observational cohort study with four participating centers of the Eunice Shriver National Institute of Child Health and Human Developmentsponsored Obstetric-Fetal Pharmacology Research Units Network including the University of Texas Medical Branch, Indiana University, University of Washington, and University of Pittsburgh. Approval was obtained from the Institutional Review Board of each center. The primary aims of this study were to assess the relationship between pregnancy history and 17-OHPC treatment on the cervical fluid proteome, cytokines, MMPs, and cervical length and density in three groups of women: control subjects (n ¼ 26) had a history of one or more term births and no PTBs. The 17-OHPC group (n ¼ 24) had a history of one or more prior SPTBs and chose to receive 17-OHPC intramuscular injections weekly starting between 16 and 20 weeks until 36 weeks' gestation, while refuser women (n ¼ 12) had a history of one or more SPTBs but declined to receive 17-OHPC. All subjects with a prior SPTB were enrolled after they and their providers had decided whether or not the subject would accept 17-OHPC treatment. They were not randomized to the two study groups; receipt or nonreceipt of 17-OHPC was a clinical decision. We evaluated four MMPs including MMP-1, MMP-2, MMP-8, and MMP-9 and eight cytokines including interleukin (IL)-1α, IL-1β, IL-4, IL-6, IL-8, IL-10, IL-13, and tumor necrosis factor (TNF)-α. We first compared baseline concentrations of these analytes and then compared concentrations during 8 weeks of study by group. In particular, we evaluated the impact of 17-OHPC treatment on trends in the MMP and cytokine concentrations over 8 weeks of observation. The primary comparisons focus on the 17-OHPC group and the controls. Comparisons between the two groups of women with a prior SPTB, that is, 17-OHPC and refuser groups are also reported. This report focuses on the MMP and cytokine comparisons. Analyses of the proteomic, ultrasound, and pharmacogenomic analyses will be reported separately.
The study also planned to recruit a fourth group of asymptomatic women with a short cervix detected on routine ultrasound who agreed to receive vaginal progesterone. However, only five subjects were recruited in this arm; therefore, this cohort of women was excluded from this report. Entry criteria for the three study groups are listed in the ►Appendix.
Study Procedures
All subjects fulfilling entry criteria and consenting to the study were scheduled to undergo four visits: the first within 1 to 2 weeks of enrollment and prior to any progestin therapy in the 17-OHPC group. This baseline visit was followed by three additional visits at 2, 4, and 8 weeks after the baseline visit. These time points were selected both to detect early changes in measured parameters and also to allow adequate time for any treatment effects to be detected. At each of these visits, a sterile speculum examination was performed without gel. Two Dacron-tipped swabs were placed in the external cervix for 1 minute for collection of cervical fluid. The first swab was designated for proteomic analysis; the second swab was designated for cytokine and MMP assay. Subsequently, a third swab was placed in the posterior fornix for 1 minute for future analyses of other potential biomarkers. A fourth swab was then placed in the posterior fornix for determination of bacterial vaginosis (BV) followed by a fifth swab which was placed in the cervix for determination of gonorrhea, chlamydia, and trichomonas using assay methods typically used at each institution. The swab for cytokines and MMP analysis was placed in a 2-mL cryovial containing 400 μL of Dulbecco's phosphate-buffered saline (DPBS), swirled for 10 seconds, then the tip was cut and left in the vial, labeled, and frozen at À80°C. The swabs for proteomic analysis and other future studies were placed into a 2-ml cryovial containing 1 mL DPBS and agitated for 10 seconds while in the DPBS then discarded. The cryovials were labeled and frozen at À80°C. The swabs for BV, trichomonas, chlamydia, and gonorrhea were sent to the institutions local laboratory for analysis according to local standards. Women with BV, Neisseria gonorrhoeae, or chlamydia were excluded from the study. After all cervicovaginal fluids were obtained, an ultrasound probe was placed in the vagina with gel and a cervical length measurement was obtained and a digital scan of the cervix was stored. At each visit, a 7-mL venous blood sample was obtained, centrifuged, and 1 mL aliquots of plasma frozen at À80°C until later analysis. The buffy coat was retained for DNA extraction and also frozen at À80°C.
Analytical Methods
Matrix Metalloproteinase and Cytokine Analysis
For cytokine and MMP analysis, each specimen was thawed at room temperature and the swab along with the specimen diluent was centrifuged in a spin-X centrifuge filter unit (Costar, Cambridge, MA) at 12,000 rpm for 20 minutes. Aliquots of the filtered solution were stored at À80°C until analysis. Protein levels of cytokines and MMPs in the cellfree supernatants were measured (pg/mL) in duplicate through multiplexing with the use of magnetic bead kits (EMD Millipore, Billerica, MA) according to the manufacturer's instructions and analyzed on a MAGPIX (Luminex, Austin, TX) using the xPONENT 4.2 software. Multiplexing allows for quantitative measurements of multiple analytes in a small volume of fluid (25 μL) and is based on attachment of the cytokines and MMPs to magnetic beads and processing using light-emitting diode excitation. The minimum detectable concentrations (pg/mL for all analytes) defined by the manufacturer were IL-1α
. For values below the detection limit, we imputed the mid-point between 0 and the lowest threshold.
Measurement of 17-OHPC Concentration
The assay of 17-OHPC was performed by high performance liquid chromatography-mass spectrometry; our methodology for this assay has been reported . Assay limit of detection was 1 ng/mL.
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The sample size calculation for each group was 25 subjects/group, but the study was stopped before recruitment was completed as the funding cycle ended. SPSS version 23 was used for statistical analysis (IBM, 2014). As the variables measured were skewed toward zero and did not conform to a normal distribution, generalized linear mixed models were used to analyze the estimated mean difference for each variable over time and between groups at each time point. The p-values <0.05 were considered significant and the estimated p-value was adjusted to the least significant difference between Bonferroni and Sidak sequential adjustments. Statistical evaluation of trends in significant differences in inflammation markers over time and between the experimental and control groups were examined through models that controlled for the demographic variables that significantly varied among the cohorts as shown in ►Table 1.
Mean and proportional differences corresponding to the demographic variables were estimated using analysis of variance for the continuous variables that were normally distributed and Kruskal-Wallis' tests for the noncontinuous and continuous variables that were not normally distributed. A determination of normality for each demographic variable was made through the Shapiro-Wilk's statistic. We present baseline data utilizing box and whisker plots to demonstrate the variability in the analyte concentrations. For the longitudinal data, we utilized mean data without adding a measure of variance to optimize the visual presentation of the data. Significant differences in both instances are based on the statistical analyses described earlier.
Results ►Table 1 summarizes the recruited subjects by study group. There were no differences between groups in age, the proportion of African American and Caucasian subjects and body mass index. There were anticipated differences between groups in the number of SPTBs based on inclusion criteria (e.g., control women had no prior PTBs). Notable differences were seen in pregnancy history among the two groups of women with a prior SPTB. The 17-OHPC women delivered earlier than the refuser women whether evaluated by the mean gestational age of the earliest SPTB 24.4 AE 5.6 versus 30.5 AE 4.3 or by the mean gestational age of all SPTBs, 24.6 AE 5.7 versus 30.9 AE 4.4 weeks, respectively (p < 0.001 for both comparisons; ►Table 1). The gestational age at baseline was significantly earlier in the 17-OHPC group (17.3 AE 1.3 weeks) compared with the control group (20.2 AE 2.2 weeks) or the refuser group (20.6 AE 2.6), p < 0.001.The cervical length in controls (39.5 AE 6.7 mm) was significantly longer than in the other two groups at baseline (36.4 AE 6.4 mm for the 17-OHPC group and 34.0 AE 5.4 mm for the refuser group) and at 8 weeks (39.7 AE 8.5, 34.0 AE 8.7, and 33.0 AE 8.4 mm for the controls, 17-OHPC, and refusers, respectively). Despite these differences in cervical length and prior pregnancy outcome, the gestational age at delivery in the current pregnancy of women in 17-OHPC and refuser groups was similar and not significantly different than the gestational age at delivery of the controls.
Matrix Metalloproteinases and Cytokine Values at Baseline
17-OHPC versus Control Groups
At baseline, prior to any treatments, comparison of the control and 17-OHPC groups, respectively (mean AE standard deviation [SD]) demonstrated significant elevations of five cytokines in the 17-OHPC group (►Fig. 1A, B):
TNF-α (38 AE 56 vs. 136 AE 282 pg/mL), IL-6 (711 AE 1,009 vs. 1,256 AE 1,432 pg/mL), IL-8 (42,830 AE 42,284 vs. 142,226 AE 288,667 pg/mL), 1L-10 (42 AE 40 vs. 84 AE 107 pg/mL), and IL-13 (24 AE 17 vs. 35 AE 22 pg/mL). At baseline, none of the MMPs from the 17-OHPC group was significantly different than the control group, but a trend toward significance was seen for MMP-1, p < 0.08 and MMP-9, p < 0.07 (►Fig. 2).
17-OHPC versus Refuser Groups
Baseline concentrations of the cytokines, TNF-α (136 AE 282 vs. 33 AE 47 pg/mL), IL-6 (1,255 AE 1,432 vs. 392 AE 322 pg/ mL), and IL-10 (84 AE 107 vs. 39 AE 30 pg/mL), were significantly higher in the 17-OHPC group than in the refuser group, while concentrations of IL-8 were elevated but not significantly so (p < 0.06) in the 17-OHPC group when compared with the refuser group (►Fig. 1A, B). Among the MMPs, MMP-2 was significantly higher (p < 0.005) in the 17-OHPC group (5,776 AE 5,298 vs. 1,797 AE 1,926 pg/mL) than the refuser group, but there were no significant differences between any of the other MMPs (►Fig. 2).
Controls versus Refuser Groups
There were no significant differences at baseline between these two groups in any of the MMPs or cytokines evaluated.
Relationship between Gestational Age at Earliest PTB and Cytokine Concentrations at Baseline
To ascertain if gestational age at earliest delivery was predictive of cytokine concentration in those women with a prior SPTB, we evaluated the relationship between the earliest gestational age at delivery of all women with a SPTB (17-OHPC and refuser groups) and the plasma concentrations of the five cytokines that differed significantly at baseline from the controls (IL-6, IL-8, 1L-10, IL-13, and TNF-α). Gestational age at earliest SPTB was significantly related to plasma concentrations of IL-6, IL-10, and TNF-α at baseline (►Fig. 3A-C) but not to the other two cytokines. ►Fig. 3A-C depict the mean values for IL-6, IL-10, and TNF-α by three gestational age epochs. The relative concentration of cervical fluid cytokines differed significantly between those women whose earliest SPTB occurred at 16 to 23 weeks epoch as opposed to the other delivery epochs. Comparing cervical cytokine concentrations, the women in 16 to 23 weeks epoch to those of women in 32 to 36 weeks epoch (after adjusting for all the demographic variables included in ►Table 1), the relative cytokine concentration ratios were: 3.37 for IL-6 (95% confidence interval [CI], 1.08-10.53, p < 0.05), 2.81 for IL-10 (95% CI, 1.39-5.70, p < 0.05), and 6.34 for TNF-α (95% CI, 2.19-18.68, p < 0.001). Similarly, the relative cytokine concentration Fig. 1 (A, B) Boxplot of (A) proinflammatory and (B) anti-inflammatory cytokines at baseline. In each box and whisker plot, the dark line in the box represents the mean log n value, while the shaded area represents the interquartile range (i.e., between the 25th and 75th percentiles). The whisker represents the maximum and minimum values. Significance levels among the three groups are indicated with the numerical value above the arrows. When differences were p > 0. 
Gestational and Treatment Effects on MMPs and Cytokines
The mean values at each of the four-study time point for the three groups (controls, 17-OHPC, and refusers) are depicted in ►Figs. 4A, B and 5. In the control group over 8-week study period, there were no significant gestational age-related changes from baseline in cytokines or MMPs. In the 17-OHPC group, TNF-α, IL-6, and IL-8 were elevated at baseline and remained significantly elevated compared with the control group over the entire 8-week period. These cytokines were frequently elevated compared with the refuser group but not at all time points. None of these three cytokines or any of the other measured cytokines was significantly impacted by 17-OHPC treatment (►Fig. 4A, B); however, a decrease was seen in TNF-α, but the decrease was not significant either at 4-week period (p ¼ 0.2) or 8-week period (p ¼ 0.2). Among the MMPs evaluated, MMP-8 and MMP-9 did not differ over 8-week study among the three groups, but MMP-1 and MMP-2 were elevated in the 17-OHPC group throughout the first 4 weeks of study (►Fig. 5). Interestingly, both MMP-1 and MMP-2 in the 17-OHPC group demonstrated a significant decrease in concentration between 4-and 8-week time points (p < 0.02 and p < 0.03, respectively).
►Fig. 6 depicts trough 17-OHPC concentrations (mean AE SD) over 8 weeks of the study. With weekly 250 mg intramuscular dosing, trough 17-OHPC plasma concentrations were 8.2 AE 4.5 ng/mL at week 2, 10.2 AE 4.5 ng/mL at week 4, and 11.5 AE 5.5 ng/mL at week 8.
Comment
The objective of this study was to compare cervical cytokines and MMPs in women with different risk profiles for PTB prior to any treatment and then to evaluate the impact of 17-OHPC on cervical cytokines and MMPs. Each subject served as her own control longitudinally during the study, and we recruited parous women with no history of prior PTB to serve as controls for any potential gestational age effects. Each subject was studied longitudinally over 8 weeks to allow ample time for the treatment to exert its effect.
The most significant findings of this study were the elevated baseline cytokine profiles (IL-6, IL-8, Il-10, IL-13, and TNF-α) and MMP profiles (MMP-1 and MMP-2) observed 
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in the cervical fluid of women with a history of prior PTB who accepted but had not yet received 17-OHPC treatment as opposed to women with a history of only term births. The baseline cervical fluid analysis was performed between 16 and 22 weeks; none of the women was at imminent risk of PTB nor did they have a short cervix or any other clinically apparent evidence that the parturitional process had started. These cervicovaginal profiles reflect the variations in the cervical fluid immunologic milieu of these subjects. It is not surprising that women with a prior PTB history differ from women with only term births since prior pregnancy history is well known to be a powerful predictor of PTB risk. [17] [18] [19] [20] The demonstration of significant differences in cytokine and MMP profile between the controls and those with an early prior SPTB birth is novel and provides a potential biological link for the impact of history on subsequent birth outcomes. The other finding of clinical relevance was the baseline differences noted between those women with a prior SPTB Fig. 3 (A-C) Relationship between gestational age at earliest SPTB and (A) IL-6, (B) IL-10, and (C) TNF-α concentrations (pg/mL) at baseline. Concentration values at each gestational age epoch are mean AE SE. Significant differences between women with earliest SPTB at 16 to 23 weeks and the other groups indicated by asterisk. IL, interleukin; SE, standard of the error; SPTB, spontaneous preterm birth; TNF, tumor necrosis factor. who refused and those who accepted 17-OHPC treatment. The cytokine and MMP profiles of the women refusing 17-OHPC were more closely aligned with those of women with no prior PTB (controls). The pregnancy history of those refusing 17-OHPC differed from those accepting 17-OHPC (earliest PTB mean was 30.5 weeks for those who declined 17-OHPC vs. 24.4 weeks for those accepting 17-OHPC). The mean gestational age of prior PTBs was 31.4 weeks for those who refused and 24.4 weeks for those who accepted the 17-OHPC. Thus, the choice to refuse 17-OHPC treatment is not altogether surprising given the differences in history in those women compared with the history of those who accepted treatment. The data presented here suggest that women with a prior PTB are a heterogeneous group relative to their cervical inflammatory milieu and PTB risk. What is unclear is how those differences in cervical inflammatory milieu impact SPTB risk. The cervical length in those who accepted 17-OHPC and those refusing 17-OHPC was similar throughout the study. Thus, one must conclude that the elevated cytokines or MMPs in the group accepting 17-OHPC were not major determinants of cervical length. Despite the fact that those who chose to receive 17-OHPC had very early PTBs and elevated cytokines and MMPs, the gestational age at delivery was similar to those women who refused 17-OHPC as well as those women without a prior SPTB.
There are two plausible explanations for the better than expected gestational age at delivery among the women who were at high risk for SPTB and who accepted 17-OHPC. First, one could suggest that the cytokine and MMP elevations and history had little to do with the gestational age at delivery and these women were destined to deliver at term. This explanation ignores the well-established relationship of prior history to recurrent SPTB and the predictive value of cytokines such as IL-6 in predicting risk for PTB. 10, 12, 14, [21] [22] [23] [24] [25] The risk of recurrent PTB in women with a prior PTB is approximately 31%. 17 The risk is nearly 65% for those whose prior SPTB occurred prior to 28 weeks' gestation 17 and since the women who accepted 17-OHPC delivered at an average of 24 weeks' gestation, their risk of SPTB would be expected to be in this range. Cervical IL-6 concentrations appear to predict the risk for PTB with a positive predictive value of 50%. 23 In one study, an IL-6 value > 660 pg/mL at 30 to 31 weeks' gestation had a positive predictive value for predicting PTB of 85%. 24 The mean baseline value of IL-6 in the group accepting 17-OHPC in the current report was 1,256 pg/mL. Thus, by both these predictors of risk, the group of women electing to receive 17-OHPC was at considerable risk for recurrent SPTB making the first possible explanation of our findings difficult to accept. The second possible explanation of our findings is that the 17-OHPC contributed to the good pregnancy outcome in women who received that treatment either by a delayed and unobserved effect on the biomarkers we studied or by affecting other progesterone responsive genes that modulate the parturitional process. It is conceivable that 17-OHPC affected some of the biomarkers we studied after 8 weeks of observation and that with a longer period of surveillance, changes in the cytokines and MMPs would be observed. Plasma concentrations of 17-OHPC require approximately 80 days (11þ weeks) to achieve steady state, 26 but concentrations in plasma in this study were near steady state by 4 weeks. At 2 weeks, 17-OHPC trough plasma concentrations in our study averaged 8 ng/mL which our previous work suggests is subtherapeutic. 3 It is intriguing that the MMP-1 and MMP-2 decreased significantly in our study between 4-and 8-week measurements when plasma 17-OHPC concentrations would be near steady state. We did not attempt to measure 17-OHPC in the cervical fluid or cervical tissue as concentrations are likely to be too low to quantify. Such measurements might better reflect the potential impact of the medication on the biomarkers studied. Whether this reduction in both MMP-1 and MMP-2 can be attributed to 17-OHPC is unclear and requires confirmation. In addition to the possibility that longer periods of observation might have demonstrated an effect of 17-OHPC on cytokines and MMPs, it is unclear if higher doses of 17-OHPC could have impacted the biomarkers investigated in this study. Relevant to this discussion are the data from Facchinetti et al who administered 682 mg 17-OHPC weekly to women after an episode of threatened PTB.
27 Over a brief 21-day observation period, no changes were reported in cervical IL-6, IL-8, or TNF-α; however, unlike our study, a significant reduction on IL-1β was seen. These women in the study by Facchinetti et al demonstrated a lower rate of cervical shortening than the control women. Whether higher doses of 17-OHPC such as those used by Facchinetti et al would have affected any of the cytokines or MMPs in our 8-week study is unclear, but we speculate that higher doses would lead to proportionally higher concentrations of drug in the cervix or cervical fluid.
If one assumes that cytokines and MMPs were not the targets of 17-OHPC in our study, 17-OHPC could have exerted a beneficial effect on pregnancy length by impacting other progesterone responsive genes. Progestins such as 17-OHPC affect many processes in the prematurity pathway that impact the cervix, myometrium, and decidua. In the cervix, progesterone modulates the expression of genes involved in regulation of epithelial and endothelial permeability and metabolism of components of the extracellular matrix.
14 Progesterone also inhibits the ripening process by suppressing the production of prostaglandins. In the myometrium, progestins affect gap junctions and several membrane channels that affect uterine contractility.
Our study did not identify with certainty a pharmacodynamic target for 17-OHPC among those cervical cytokines and MMPs studied. Thus, these analytes could not be used as biomarkers by which to establish an optimal dosing regimen for 17-OHPC at this time. The finding that women with very early SPTBs exhibit an inflammatory cervical milieu suggests that enhanced risk profiling might be established utilizing history and a cervical biomarker such as IL-6 to better estimate risk and potentially target treatments. Such enhanced risk profiling could allow the enrollment of an enriched population of very high-risk women for clinical trials evaluating therapies. The data from this study also demonstrate the potential for dilution of benefit in clinical studies that have evaluated or will evaluate 17-OHPC efficacy in the future. Inclusion of women such as those who refused 17-OHPC in this study would greatly dilute the effect size of any treatment since the risk of recurrence is small in such women.
The small sample size is a clear limitation of this study, particularly our inability to recruit more subjects to the refuser group. This likely represents the widespread acceptance of 17-OHPC treatment for women with a prior PTB.
Despite the small sample size, we were able to demonstrate a significant relationship between the cervical fluid milieu and gestational age at the earliest prior SPTB and to evaluate the impact of 17-OHPC treatment on multiple markers of inflammation and MMPs.
In conclusion, we have demonstrated that at a dose of 250 mg weekly, 17-OHPC does not significantly alter the cytokines studied but an effect on MMP-1 and MMP-2 cannot be ruled out. We have also identified heterogeneity of cytokine concentrations in the cervical fluid milieu among the women with a prior SPTB. Those women with a prior early PTB demonstrate an inflammatory milieu that is not seen in women with term deliveries or women with a prior SPTB that occurred at a later gestational age. This inflammatory signature suggests the possibility of additional risk stratification that would enable a more specific risk-targeted treatment approach.
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